by Eric Christianson | Feb 18, 2024 | Clinical Guideline Updates For Pharmacists, Endocrine Medication and Disease State Clinical Pearls
The 2024 ADA guidelines were released a month or two ago and I wanted to take a little time to digest them before providing my big takeaways. The 2023 guidelines saw a major shift in pharmacotherapy with a strong emphasis on compelling indications and recommended...
by Eric Christianson | Feb 14, 2024 | Endocrine Medication and Disease State Clinical Pearls
When treating hyperglycemia there are two terms that I have seen get confused and often used interchangeably (inappropriately so). Sliding scale and correction factor insulin strategies are NOT the same. These can be tough concepts to differentiate use and know when...
by Eric Christianson | Feb 11, 2024 | Endocrine Medication and Disease State Clinical Pearls
With many insulin formulations on the market, it can be hard to differentiate between similar-acting products and what the best choice may be for our patients. One question raised is what the differences between Novolog versus Fiasp are due to both being insulin...
by Eric Christianson | Feb 7, 2024 | Endocrine Medication and Disease State Clinical Pearls
Diabetic Ketoacidosis (DKA) is traditionally characterized by the triad of hyperglycemia, metabolic acidosis, and ketoacidosis. However, approximately 3% of DKA cases are caused by Euglycemic DKA (EDKA). In the past, this percentage was significantly lower, but the...
by Eric Christianson | Jan 3, 2024 | Cardiovascular Case Studies
In this hypertension case study, JD is a 64-year-old male who has a history of hypertension, GERD, gout, diabetes, constipation, and sexual dysfunction and presents with the following medication list. Hydrochlorothiazide 25 mg daily Amlodipine 5 mg daily Omeprazole 20...
